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Abstract
Background: We previously developed an assay to directly measure small dense (sd) low-density lipoprotein
cholesterol (LDL-C) levels, which is not widely used in general clinical practice. Therefore, we propose a simpler
method, “LDL window,” that uses conventional methods for estimating high sdLDL-C levels.
Methods: We analyzed our previous studies (2006–2008) on healthy subjects and patients with type 2 diabetes and
coronary artery disease (CAD). The sdLDL-C level was measured using the precipitation method, and LDL size was
determined using gradient gel electrophoresis. The “LDL window” comprises the estimation of LDL particle number
and size. We adopted apolipoprotein B (apoB) for the estimation of the LDL particle number and used 110 mg/dL as
the cutoff value for hyper-apoB. Triglycerides (TGs) are a powerful inverse determinant of LDL particle size. Therefore,
we adopted TG for the estimation of the LDL particle size and used 150 mg/dL as the cutoff value for hyper-TG.
Subjects were stratified into the following four subgroups: normal, hyper-TG, hyper-apoB, and hyper-TG/-apoB. Non-
high-density lipoprotein cholesterol (non-HDL-C) is a surrogate marker for apoB; therefore, the “alternative LDL
window” comprised non-HDL-C (cutoff, 170 mg/dL) and TG.
Results: The top quartile (Q4) of sdLDL-C (>31 mg/dL) doubled in patients with diabetes and CAD. The hyper-TG/-apoB
group in the “LDL window” represented >90% Q4 and <4% Q1 and Q2, irrespective of the subjects. The sdLDL-C levels in
the hyper-TG/-apoB group were 50% higher in patients with diabetes and CAD than those in controls. Similar results
were obtained using the “alternative LDL window.”
Conclusions: Our proposed “LDL window” may help identify patients at high risk of CAD independent of LDL-C.
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Background
Low-density lipoprotein (LDL) is an atherogenic factor
that can be fractionated into large buoyant (lb) and small
dense (sd) particles according to size and density [1].
Abundant clinical evidence shows that sdLDL particles
are more atherogenic than lbLDL particles [2–5], and
the predominance of sdLDL incurs a three-fold increase
in the risk for coronary artery diseases (CADs) [2–6].
The prospective Québec cardiovascular study revealed
that a greater proportion of sdLDL, evaluated semi-
quantitatively, is a significant and independent predictor
of CAD [7]. Our group previously developed a simple
precipitation assay for the selective and direct measure-
ment of the sdLDL levels in serum or plasma [8] and
demonstrated that not lbLDL-cholesterol (C) but the
sdLDL-C levels were closely related to the angiographic
and/or clinical severity of CAD independent of classical
coronary risk factors [9, 10]. In a similar manner, using
our method, a case-control analysis of the Framingham
Offspring study revealed that the sdLDL-C/LDL-C ratio
was significantly higher in subjects with CAD than that
in those without CAD, regardless of sex [11]. Recent
large cohort studies using our homogenous method [12]
found that sdLDL-C is superior to conventional lipid
measurements for predicting CAD risk [13–15].
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However, the measurement of the sdLDL-C levels is not
widely employed in general clinical practice.
Here we propose “LDL window” for estimating individ-
uals with high sdLDL-C levels stratified according to the
plasma triglyceride (TG) and apolipoprotein B (apo B)
levels or non-high-density lipoprotein cholesterol (non-
HDL-C).
Methods
We developed a method using conventional lipid mea-
surements to better facilitate the identification of indi-
viduals with high sdLDL-C levels and determined
whether the significance of sdLDL-C is potentiated in
patients with diabetes and CAD. The present study rep-
resents an analysis of our previous studies conducted
during 2006–2008 that measured the sdLDL-C level and
LDL size of healthy subjects (n = 1665) [16], patients
with type 2 diabetes (n = 201), and patients with CAD
without or with type 2 diabetes (n = 528, 354/174).
Healthy subjects were employees of Denka Seiken Co.
All patients with type 2 diabetes were diagnosed accord-
ing to the criteria provided by the Japanese Diabetes
Association. All patients with CAD exhibited significant
coronary stenosis that was detected using coronary angi-
ography. We excluded patients taking lipid-lowering
agents [17–20]. During the previous study, patients with
CAD or type 2 diabetes were not frequently treated
using statins. Written informed consent was obtained
from all individuals, and the local ethics committee
approved the experimental protocol.
Measurements
All plasma samples, which were obtained after the
patients fasted overnight, were stored at –80 °C. The
sdLDL-C level was measured using heparin–magnesium
precipitation [8], and LDL particle size was measured
using nondenaturing gradient-gel (2%–16%) electrophor-
esis (GGE) according to a published method [21]. Particles
with diameters of <25.5 nm were determined of having
the small-sized LDL phenotype, pattern B [22]. ApoB was
measured using a turbidometric assay (Sekisui Kagaku
Co.). Total-C, TG, LDL-C, HDL-C, and HbA1c levels
were measured using standard laboratory procedures.
lbLDL-C was estimated by subtracting the sdLDL-C level
from the LDL-C level. Non-HDL-C was calculated by
subtracting the HDL-C level from the total-C level.
HbA1c (National Glycohemoglobin Standardization Pro-
gram [NGSP]) values were estimated by 1.02 ×HbA1c
(Japan Diabetes Society[JDS]) + 0.25% [23].
Quantile analysis of sdLDL-C
The sdLDL-C levels in healthy subjects (n = 1665)
were stratified into quartiles (Q) as follows: Q1,
<15.4 mg/dL; Q2, 15.4–21.9 mg/dL; Q3, 22.0–31.7 mg/dL;
and Q4, >31.7 mg/dL. Patients with diabetes and CAD
were similarly analyzed.
Determination of hyper-apoB
The apoB levels correspond to non-HDL-C levels. The
Japanese Atherosclerosis Society has not decided the
designation of hyper-apoB. Therefore, we measured
non-HDL-C, a surrogate marker for apoB [24], to deter-
mine the cutoff level of hyper-apoB. Non-HDL-C levels
correlated highly with apoB levels in 1665 healthy
subjects (Y = 1.404X + 9.48, R2 = 0.94, p < 0.0001) (Fig. 1),
and the value of high non-HDL-C (170 mg/dL) [24] cor-
responded to 113 mg/dL of apoB. Thus, we used
110 mg/dL as the cutoff value for hyper-apoB.
Surrogate marker of LDL size
Small LDL particles were defined as those with an aver-
age diameter of <25.5 nm, the so-called pattern B [22].
TG is a powerful inverse determinant of LDL particle
size [22]. In contrast, the sdLDL particle is cholesterol
depleted. Therefore, the LDL-C/apoB ratio positively
correlates with the diameter of the LDL particle [25].
When we compared whether the TG or LDL-C/apoB
ratio more strongly correlated with LDL particle diame-
ters, we found that TG is more strongly correlated with
LDL size (r = –0.52 vs. 0.44 data not shown). Therefore,
we selected TG as a surrogate marker for LDL size. The
TG/HDL-C ratio strongly correlates with LDL diameter
[26]. However, we could not detect an additive effect of
TG/HDL-C on improving the correlation with LDL size
beyond TG (data not shown).
The “LDL window” and the “alternative LDL window”
We proposed the “LDL window” and the “alternative
LDL window” for estimating high sdLDL-C. Figure 2
shows its usage. The “LDL window” comprises the num-
ber and sizes of LDL particles estimated according to
the plasma apoB and TG levels, respectively. The cutoff
values of the hyper-apoB and -TG levels were 110 and
150 mg/dL, respectively. Subjects were stratified into the
subgroups as follows: normal (apoB <110 and TG
<150 mg/dL), hyper-TG (apoB <110 and TG ≥150 mg/dL),
hyper-apoB (apoB ≥110 and TG <150 mg/dL), and hyper-
TG/-apoB (apoB ≥110 and TG ≥150 mg/dL).
The “alternative LDL window” comprises the number
and sizes of LDL particles estimated according to the
plasma non-HDL-C and TG levels.
Non-HDL-C is a surrogate marker for apoB [22];
therefore, it was used instead of apoB, and subjects were
grouped as follows: normal (non-HDL-C <170 and TG
<150 mg/dL), hyper-TG (non-HDL-C <170 and TG
≥150 mg/dL), hyper-non-HDL (non-HDL-C ≥170 and
TG <150 mg/dL), and hyper-TG/-non-HDL (non-HDL-
C ≥170 and TG ≥150 mg/dL).
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Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Statistical analyses were performed using JMP 11.0 (SAS
Institute, Cary, NC, USA). Comparisons among multiple
groups were performed using one-way analysis of vari-
ance, and statistical significance was evaluated using the
Bonferroni–Dunn post-hoc test. Pearson’s linear regres-
sion analysis was used to evaluate the relationship
between the apoB and non-HDL-C levels in healthy
subjects. Significance was defined as p < 0.05.
Results
Table 1 shows the general and metabolic characteristics
of all subjects. The mean age of patients with CAD was
greater than that of healthy subjects and patients with
diabetes. Among patients with CAD, 33% were diagnosed
Fig. 2 The flowchart of the use of the “LDL window” and the “alternative LDL window” for estimating high sdLDL-C
Fig. 1 Correlations between non-HDL cholesterol (C) and apoB in healthy subjects (n = 1665). The curve-fitting parameters are Y = 1.404X + 9.48,
R2 = 0.94, p < 0.0001
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with diabetes. TG levels were significantly higher in
patients with CAD and diabetes than those in healthy
subjects. HDL-C levels were lower in patients with CAD
or diabetes than those in healthy subjects. LDL-C, non-
HDL-C, and apoB levels were higher in patients with
CAD than those in healthy subjects and were further ele-
vated in patients with diabetes. The mean plasma sdLDL-
C levels and sdLDL-C/LDL-C ratios were 25 mg/dL and
21.6%, respectively, in the healthy subjects. The sdLDL-C
levels were higher in patients with CAD than those in
healthy subjects and were further increased in patients
with diabetes. The lbLDL-C levels were lower in patients
with CAD than those in healthy subjects. The mean LDL
size was smaller in patients with diabetes than that in
healthy subjects and even smaller than that in patients
with CAD. The LDL-C/apoB ratios were significantly
lower in patients with CAD or diabetes than those in
healthy subjects, which was consistent with the differ-
ence in LDL size.
Table 2 lists lipid profiles of healthy subjects stratified
according to their sdLDL-C quartile. The total-C, TG,
LDL-C, lbLDL-C, non-HDL-C, and apoB levels and
sdLDL-C/LDL-C ratios were significantly increased, and
LDL sizes decreased with the increase in the sdLDL-C
quartile. The LDL/apoB ratios were similar between
Q1 and Q3 and significantly decreased in Q4. The
representations of the small-LDL phenotype (pattern
B) in Q4 were 36.9 and 2.4% in Q1.
Table 3 lists the characteristics and lipid measure-
ments of healthy subjects in the “LDL window.” The
majority (75.7%) of healthy subjects were stratified into
the normal group and 6.5% were included in the hyper-
TG/-apoB group. The hyper-TG/-apoB group had the
lowest HDL-C levels and smallest LDL size. The repre-
sentation of pattern B in the hyper-TG/-apoB group was
56.5%, and the normal group represented 6.4%. Total-C
levels were similar between the hyper-apoB and hyper-
TG/-apoB groups. The LDL-C and lbLDL-C levels were
the highest in the hyper-apoB group, whereas the
sdLDL-C levels were the highest in the hyper-TG/-apoB
group. The sdLDL-C levels were 1.5-fold higher in the
hyper-TG group, 2-fold higher in the hyper-apoB group,
and 2.5-fold higher in the TG/hyper-apoB group than
those in the normal group. The hyper-TG/-apoB repre-
sented 90.7% of Q4 and 0.9% and 2.8% of Q1 and Q2,
respectively.
Table 4 lists the characteristics and lipid measure-
ments of patients with type 2 diabetes in the “LDL
window.” Approximately 20% of the patients with type 2
diabetes were classified into the hyper-TG/-apoB group,
which was 3-fold higher than the percentage of healthy
subjects. The total-C, TG, non-HDL-C, and apoB levels
were the highest and LDL sizes were the smallest in the
hyper-TG/-apoB group. The prevalence of pattern B was
61.5 and 17.1% in the hyper-TG/-apoB and normal
groups, respectively. The LDL-C levels were similar
between the hyper-apoB and the hyper-TG/-apoB
groups. The lbLDL-C levels were the highest in the
hyper-apoB group, whereas the sdLDL-C levels were the
highest in the hyper-TG/-apoB group. The sdLDL-C
levels in the hyper-TG/-apoB group were 2.8-fold higher
than those in the normal group. The Q4 of sdLDL-C
distributed in the hyper-TG/-apoB was 92.3 and 0% in
Q1 and Q2.
Table 5 shows the characteristics and lipid measure-
ments of patients with CAD in the “LDL window.”
Approximately 40% of these patients were classified into
the hyper-TG/-apoB group. The total-C and LDL-C
levels were similar between the hyper-apoB and hyper-
TG/-apoB groups. Non-HDL-C and apoB levels were
the highest in the hyper-TG/-apoB group. LDL sizes
were smaller in the hyper-TG and hyper-TG/-apoB
groups than those in the normal group. The frequencies
of pattern B were 77.6 and 80.5% in the hyper-TG and
hyper-TG/-apoB groups, respectively, and were 35.6 and
39.7% in the normal and hyper-apoB groups, respect-
ively. The lbLDL-C levels were the highest in the hyper-
apoB group, whereas the sdLDL-C levels were the
highest in the hyper-TG/-apoB group. The sdLDL-C
levels in the hyper-TG/-apoB group were 2.3-fold higher
Table 1 General and metabolic characteristics of the healthy
subjects, patients with coronary artery disease (CAD), and patients
with type 2 diabetes (Diabetes)
Healthy subjects CAD Diabetes
Number 1665 528 201
Age, years 41 ± 12 67 ± 11a 61 ± 12a,b
Sex, M/F 954/711 414/114 125/76
Diabetes, n (%) 0 174 (33) 201 (100)
Total cholesterol, mg/dl 195.5 ± 33.5 197.1 ± 36.4 205.3 ± 49.6a,b
HDL-C, mg/dl 62.0 ± 15.3 47.2 ± 13.5a 48.2 ± 13.3a
TG, mg/dl 95.0 ± 65.2 131.5 ± 76.1a 142.0 ± 85.1a
LDL-C, mg/dl 113.9 ± 31.6 119.6 ± 32.4a 129.2 ± 40.4a,b
sdLDL-C, mg/dl 25.0 ± 13.0 35.3 ± 20.5a 40.3 ± 24.9a,b
lbLDL-C, mg/dl 88.9 ± 24.9 84.3 ± 29.1a 88.9 ± 31.7
Non-HDL-C, mg/dl 133.4 ± 33.7 149.9 ± 35.5a 157.1 ± 47.4a,b
sdLDL-C/LDL-C, % 21.6 ± 8.3 29.6 ± 15.0a 30.5 ± 14.5a
ApoB, mg/dl 88.3 ± 23.4 98.0 ± 23.6a 105.3 ± 31.4a,b
LDL-C/apoB 1.29 ± 0.12 1.22 ± 0.17a 1.23 ± 0.12a
LDL size, nm 26.1 ± 0.51 25.6 ± 0.41a 25.8 ± 0.50a,b
Data are expressed as mean ± standard deviation
Significance at p < 0.0001–0.05 by ANOVA
CAD coronary artery disease, HDL-C high-density lipoprotein-cholesterol, TG
triglyceride, LDL-C low-density lipoprotein-cholesterol, sdLDL-C small dense
LDL-C, lbLDL-C large buoyant LDL-C, Non-HDL-C non high-density
lipoprotein-cholesterol, Apo apolipoprotein
avs. Healthy subjects; bvs. CAD
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Table 3 LDL window in 1665 healthy subjects
“LDL window”
Groups Normal Hyper-TG Hyper-apoB Hyper-TG/-apoB
Number (M/F) 1261 (617/644) 100 (86/14) 196 (152/43) 108 (98/10)
%N/total N 75.7 6.0 11.8 6.5
Total cholesterol, mg/dl 185.4 ± 27.5 190.9 ± 23.0 239.9 ± 22.5a,b 236.3 ± 24.5a,b
HDL-C, mg/dl 64.7 ± 15.1 50.3 ± 12.0a 57.7 ± 13.1a,b 48.8 ± 10.0a,c
TG, mg/dl 72.3 ± 28.6 224.1 ± 89.7a 102.8 ± 26.7a,b 225.9 ± 93.2a,c
LDL-C, mg/dl 103.6 ± 23.9 108.1 ± 22.2 162.2 ± 19.0a,b 151.3 ± 25.2a,b,c
sdLDL-C, mg/dl 20.4 ± 8.9 31.2 ± 10.8a 37.2 ± 11.1a,b 49.2 ± 14.6a,b,c
lbLDL-C, mg/dl 83.1 ± 20.4 76.9 ± 20.4a 125.0 ± 19.5a,b 102.1 ± 23.5a,b,c
Non-HDL-C, mg/dl 120.6 ± 24.9 140.6 ± 19.8a 182.2 ± 16.8a,b 187.5 ± 23.3a,b
sdLDL-C/LDL-C, % 19.7 ± 7.0 29.3 ± 9.6a 23.0 ± 6.7a,b 32.8 ± 9.0a,b,c
ApoB, mg/dl 78.9 ± 16.0 93.9 ± 13.1a 122.6 ± 10.5a,b 128.8 ± 14.2a,b,c
LDL-C/apoB 1.30 ± 0.10 1.14 ± 0.16a 1.32 ± 0.09b 1.17 ± 0.12a,c
LDL size, nm 26.2 ± 0.41 25.5 ± 0.73a 25.8 ± 0.41a,b 25.4 ± 0.52a,c
Pattern B, n (%)* 81 (6.4) 46 (46) 55 (28.1) 61 (56.5)
sdLDL-C Q1, Q2, Q3, Q4, n 407, 391, 328, 135 6, 14, 27, 53 1, 8, 56, 131 1, 3, 6, 98
sdLDL-C Q1, Q2, Q3, Q4, % 32.3, 31.0, 26.0, 10.7 6.0, 14.0, 27.0, 53.0 0.5, 4.1, 28.6, 66.8 0.9, 2.8, 5.6, 90.7
Data are expressed as mean ± standard deviation
HDL-C high-density lipoprotein-cholesterol, TG triglycerides, LDL-C low-density lipoprotein-cholesterol, sdLDL-C small dense LDL-C, lbLDL-C large buoyant LDL-C,
Non-HDL-C non high-density lipoprotein-cholesterol, Apo apolipoprotein, Pattern B LDL phenotype with an average diameter of <25.5 nm
Significance at p < 0.0001–0.05 by ANOVA
*Statistically significant differences
avs. normal; bhyper-TG; cvs. hyper-apoB
Table 2 Lipid measurements stratified by sdLDL-C quartiles in 1665 healthy subjects
sdLDL-C quartile Q1 Q2 Q3 Q4
(<15.4 mg/dl) (15.4–21.9 mg/dl) (22.0–31.7 mg/dl) (>31.7 mg/dl)
Number 415 416 417 417
(M/F) (182/233) (222/194) (237/180) (313/104)
Total cholesterol, mg/dl 171.8 ± 25.8 187.2 ± 28.1a 200.0 ± 27.9a,b 222.8 ± 29.4a,b,c
HDL-C, mg/dl 67.1 ± 15.0 65.3 ± 15.2 61.5 ± 14.6a,b 54.4 ± 13.4a,b,c
TG, mg/dl 67.9 ± 39.4 75.4 ± 37.4a 90.0 ± 49.4a,b 146.6 ± 88.4a,b,c
LDL-C, mg/dl 88.1 ± 21.1 104.2 ± 22.6a 120.6 ± 24.8a,b 142.6 ± 28.0a,b,c
sdLDL-C, mg/dl 11.7 ± 2.5 18.7 ± 1.94a 26.2 ± 2.7a,b 43.3 ± 10.4a,b,c
lbLDL-C, mg/dl 76.4 ± 20.4 85.6 ± 22.3a 94.4 ± 24.2a,b 99.4 ± 26.0a,b,c
Non-HDL-C, mg/dl 104.7 ± 20.9 121.9 ± 22.4a 138.5 ± 25.4a,b 168.4 ± 27.4a,b,c
sdLDL-C/LDL-C, % 13.9 ± 4.0 18.7 ± 4.5a 22.6 ± 5.1a,b 31.0 ± 7.4a,b,c
ApoB, mg/dl 67.3 ± 13.5 79.8 ± 14.3a 92.0 ± 16.6a,b 113.8 ± 18.5a,b,c
LDL-C/apoB 1.30 ± 0.12 1.30 ± 0.11 1.31 ± 0.10 1.25 ± 0.14a,b,c
LDL size, nm 26.3 ± 0.33 26.2 ± 0.48a 26.1 ± 0.43a,b 25.7 ± 0.58a,b,c
Pattern B, n (%) 10 (2.4) 20 (4.8) 59 (14.2) 154 (36.9)
Data are expressed as mean ± standard deviation
HDL-C high-density lipoprotein-cholesterol, TG triglycerides, LDL-C low-density lipoprotein-cholesterol, sdLDL-C small dense LDL-C, lbLDL-C large buoyant LDL-C,
Non-HDL-C non high-density lipoprotein-cholesterol, Apo apolipoprotein, Pattern B LDL phenotype with an average diameter of <25.5 nm
Significance at p < 0.0001–0.05 by ANOVA
avs. Q1; bvs. Q2; cvs. Q3
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than those in the normal group. The Q4 of sdLDL-C
included 96.1% of the hyper-TG/-apoB group and 0% in
Q1 and Q2. The sdLDL-C levels and prevalance of the
hyper-apoB/-TG group were not different between pa-
tients with CAD with and without diabetes (data not
shown).
The top panel of Fig. 3 depicts the sdLDL-C levels
stratified by the “LDL window” of healthy subjects,
patients with diabetes, and patients with CAD according
to the data presented in Tables 3, 4, and 5. The sdLDL-C
levels were significantly higher in the hyper-TG/-apoB
group independent of subjects’ characteristics, and these
levels were significantly higher in patients with diabetes or
CAD than those in healthy subjects. The bottom panel of
Fig. 3 shows the sdLDL-C levels stratified by the “alterna-
tive LDL window” according to non-HDL-C and TG
levels in healthy subjects and patients with diabetes or
CAD. The general and metabolic characteristics of
subjects list are shown in the Additional file 1: Table S1,
S2 and S3. The characteristics of subjects stratified by
non-HDL-C and TG levels were comparable to those
stratified by apoB and TG levels. The sdLDL-C levels were
significantly higher in the hyper-TG/-apoB group than
those in the other groups, irrespective of subjects’ charac-
teristics. Furthermore, these levels were significantly
higher in patients with diabetes and CAD than those in
healthy subjects. We compared the "LDL window" and the
"alternative LDL window" for healthy controls and diabetic
and CAD groups. There were no significant differences
between the "LDL window" and the "alternative LDL win-
dow" in the distribution of patients and sdLDL-C levels.
Discussion
The sdLDL particles may be highly atherogenic because
of their greater ability to penetrate the arterial wall, their
lower affinity for the LDL receptor, their prolonged half-
life in plasma, and their lower resistance to oxidative
stress than the lbLDL particles [1, 3]. We developed the
precipitation [8] and homogenous methods [12] for
measuring sdLDL-C. Our direct homogenous sdLDL-C
assays were employed by large cohort studies [13–15],
which revealed that the sdLDL-C levels more sensitively
predict CAD events than lbLDL-C or LDL-C levels.
Because the homogenous method was developed using
the precipitation method as a reference, the sdLDL-C
levels determined by the two methods should be identi-
cal [12], and the results acquired using each method
excellently correlated with ultracentrifugation methods
[12]. Thus, there should be no difference in interpreting
the data acquired using each assay, and the data pre-
sented here shows that using the precipitation method is
applicable to the homogenous method.
Table 4 LDL window in patients with type 2 diabetes
“LDL window”
Groups Normal Hyper-TG Hyper-apoB Hyper-TG/-apoB
Number (M/F) 105 (66/39) 19 (12/7) 38 (22/16) 39 (25/14)
%N/total N 52.2 9.5 18.9 19.4
Total cholesterol, mg/dl 176.0 ± 28.6 178.4 ± 24.8 241.7 ± 38.9a,b 261.4 ± 40.7a,b,c
HDL-C, mg/dl 49.3 ± 13.2 39.8 ± 7.9a 51.8 ± 14.5b 45.7 ± 12.6
TG, mg/dl 96.0 ± 26.5 198.4 ± 48.3a 118.0 ± 21.7b 261.3 ± 109.3a,b,c
LDL-C, mg/dl 105.6 ± 23.6 104.4 ± 20.6 168.9 ± 31.0a,b 165.8 ± 33.4a,b
sdLDL-C, mg/dl 26.4 ± 11.8 38.2 ± 17.2a 45.7 ± 18.9a 73.0 ± 27.1a,b,c
lbLDL-C, mg/dl 79.2 ± 20.1 66.1 ± 24.5 123.2 ± 34.7a,b 92.7 ± 31.8a,b,c
Non-HDL-C, mg/dl 126.7 ± 25.8 138.7 ± 22.5 189.9 ± 32.2a,b 215.7 ± 37.5a,b,c
sdLDL-C/LDL-C, % 24.9 ± 9.5 37.1 ± 15.8a 27.7 ± 13.0b 44.6 ± 15.8a,c
ApoB, mg/dl 84.6 ± 16.5 93.9 ± 13.8 128.4 ± 20.0a,b 143.7 ± 25.5a,b,c
LDL-C/apoB 1.24 ± 0.09 1.10 ± 0.12a 1.31 ± 0.09a,b 1.15 ± 0.13a,c
LDL size, nm 25.9 ± 0.44 25.6 ± 0.42 25.9 ± 0.49 25.4 ± 0.52a,c
Pattern B, n (%)* 18 (17.1) 6 (31.6) 11 (29.0) 24 (61.5)
sdLDL-C Q1, Q2, Q3, Q4, n 19, 21, 33, 32 1, 1, 6, 11 1, 3, 7, 27 0, 0, 3, 36
sdLDL-C Q1, Q2, Q3, Q4, % 18.1, 20.0, 31.4, 30.5 5.3, 5.3, 31.6, 57.9 2.6, 7.9, 18.4, 71.1 0, 0, 7.7, 92.3
Data are expressed as mean ± standard deviation
HDL-C high-density lipoprotein-cholesterol, TG triglycerides, LDL-C low-density lipoprotein-cholesterol, sdLDL-C small dense LDL-C, lbLDL-C large buoyant LDL-C,
Non-HDL-C non high-density lipoprotein-cholesterol, Apo apolipoprotein, Pattern B LDL phenotype with an average diameter of <25.5 nm
Significance at p < 0.0001–0.05 by ANOVA
*Statistically significant differences
avs. normal; bhyper-TG; cvs. hyper-apoB
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Measurement of LDL size and determination of the
prevalence of the sdLDL phenotype (Pattern B) is
important for evaluating the residual risk independent of
the LDL-C level. LDL size is typically small in individ-
uals with severe hypertriglyceridemia such as chylomi-
cronemia, although they are not considered at a high
risk for CAD [27, 28]. In contrast, individuals with
moderate hypertriglyceridemia accompanied by hyper-
cholesterolemia, including those with familial combined
hyperlipidemia [16] as well as many patients with type 2
diabetes, are at a high risk for CAD. These observations
suggest that quantification of sdLDL (sdLDL-C level) is
a more sensitive marker for risk than qualification of
LDL (LDL size) when predicting CAD.
The “LDL window” comprises LDL particle number and
size. A single molecule of apoB is the principal structural
component of the lipoprotein particles of very-low-density
lipoprotein (VLDL), intermediated-density lipoprotein
(IDL), and LDL. The long plasma residence time of LDL
compared with that of VLDL or IDL accounts for the
association of ≥90% of plasma apoB with LDL [29]. There-
fore, the plasma apoB level approximates the LDL particle
number as revealed by nuclear magnetic resonance
spectroscopy (r2 = 0.79) [30]. However, this estimation is
not applicable to patients with hypertriglyceridemia
because TG-rich lipoprotein apoB is contaminated with
plasma apoB. The discordance (LDL particle number/
ApoB) is not associated with plasma TG levels. Moreover,
the discordance (LDL-particle number > apoB) increases
with greater insulin resistance, suggesting that apoB
underestimates LDL particle number in patients with
insulin resistance that is typically accompanied by
hypertriglyceridemia. Despite these critical limitations, we
conclude that apoB serves as the best marker for LDL
particle number among conventional analytical methods.
The prevalence of the hyper-apoB/-TG group was only
6.5% in the healthy subjects studied here, and this group
in the “LDL window” represented 91% of sdLDL-C Q4
and 1% of Q1, indicating efficient detection of subjects
with high sdLDL-C levels. The sdLDL-C level was higher
in the hyper-apoB group than that in the hyper-TG
group, suggesting that an increase in LDL particle
number, rather than the decrease of LDL size, more
strongly contributed to the elevated sdLDL-C level.
Patients with type 2 diabetes often have hypertriglyc-
eridemia and mild elevation of LDL-C, both of which
are associated with a high prevalence of CAD events
[31]. We found that the elevation of LDL-C in diabetic
Table 5 LDL window in 528 patients with CAD including diabetes
“LDL window”
Groups Normal Hyper-TG Hyper-apoB Hyper-TG/-apoB
Number (M/F) 312 (244/68) 76 (67/9) 63 (46/17) 77 (57/20)
%N/total N 59.1 14.4 11.9 14.6
Diabetes, n (%) 102 (32.6) 23 (30.2) 20 (31.7) 29 (37.6)
Total cholesterol, mg/dl 180.7 ± 27.2 191.6 ± 22.8a 232.9 ± 29.7a,b 239.4 ± 29.7a,b
HDL-C, mg/dl 49.8 ± 14.3 43.7 ± 12.3a 46.1 ± 11.7 40.7 ± 8.8a
TG, mg/dl 92.1 ± 28.1 222.6 ± 86.1a 104.6 ± 32.1b 223.1 ± 70.3a,c
LDL-C, mg/dl 106.5 ± 22.9 105.9 ± 20.0 159.5 ± 25.7a,b 153.3 ± 28.3a,b
sdLDL-C, mg/dl 26.6 ± 13.9 37.6 ± 14.6a 44.1 ± 24.6a 60.8 ± 19.0a,b,c
lbLDL-C, mg/dl 79.9 ± 23.0 68.3 ± 23.9a 115.3 ± 33.5a,b 92.4 ± 31.5a,b,c
Non-HDL-C, mg/dl 130.9 ± 22.2 147.9 ± 20.8a 186.8 ± 25.9a,b 198.6 ± 26.5a,b,c
sdLDL-C/LDL-C, % 25.4 ± 13.3 36.5 ± 15.0a 28.0 ± 15.2b 40.8 ± 13.4a,c
ApoB, mg/dl 85.0 ± 14.3 94.5 ± 11.6a 124.4 ± 13.6a,b 132.2 ± 16.5a,b,c
LDL-C/apoB 1.25 ± 0.16 1.11 ± 0.15a 1.28 ± 0.14b 1.15 ± 0.13a,c
LDL size, nm 25.7 ± 0.36 25.3 ± 0.43a 25.7 ± 0.32b 25.4 ± 0.40a,c
Pattern B, n (%)* 111 (35.6) 59 (77.6) 25 (39.7) 62 (80.5)
sdLDL-C Q1, Q2, Q3, Q4, n 61, 75, 81, 95 3, 5, 23, 45 3, 5, 13, 42 0, 0, 3, 74
sdLDL-C Q1, Q2, Q3, Q4, % 19.6, 24.0, 26.0, 30.5 4.0, 6.6, 30.3, 59.2 4.8, 7.9, 20.6, 66.7 0, 0, 3.9, 96.1
Data are expressed as mean ± standard deviation
HDL-C high-density lipoprotein-cholesterol, TG triglycerides, LDL-C low-density lipoprotein-cholesterol, sdLDL-C small dense LDL-C, lbLDL-C large buoyant LDL-C,
Non-HDL-C non high-density lipoprotein-cholesterol, Apo apolipoprotein, Pattern B LDL phenotype with an average diameter of <25.5 nm
Significance at p < 0.0001–0.05 by ANOVA
*Statistically significant differences
avs. normal; bhyper-TG; cvs.hyper-apoB
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populations was solely attributable to increased sdLDL-C
[32]. Here we found that 20% of diabetic patients were
classified into the hyper-apoB/-TG group, which was 3-
fold higher than healthy subjects. The hyper-apoB/-TG
group represented 92% of sdLDL-C Q4 and 0% of Q1 and
Q2, indicating an increased discrimination between higher
sdLDL-C levels in patients with diabetes compared with
healthy subjects. SdLDL-C values in the hyper-apoB/-TG
group were increased by 50% compared with those in the
same group of healthy subjects (73 mg/dL vs. 49 mg/dL,
p < 0.0001). Thus, the “LDL window” efficiently estimated
very high sdLDL-C levels, particularly in subjects with dia-
betes. The high prevalence of sdLDL particles has been
documented in patients with CAD [33–36]. Similar to
patients with diabetes, a high prevalence of the hyper-
apoB/-TG group was observed in patients with CAD who
also had sdLDL-C levels that were 50% higher than those
of the same group of healthy subjects. There was no sig-
nificant difference in the sdLDL-C levels and prevalence
of the hyper-apoB/-TG group between patients with CAD
with and without diabetes, suggesting that diabetes is not
an obligate factor and that other mechanisms must be in-
volved in causing the hyper-apoB/-TG phenotype in
patients with CAD.
We proposed the “LDL window” stratified by apoB
and TG, but apoB is not commonly measured in general
practice. Therefore, we defined the “alternative LDL
window” that incorporates non-HDL-C instead of apoB.
Finally, we obtained comparable results between two
“LDL windows.” The “alternative LDL window” was par-
ticularly useful for identifying individuals with high
sdLDL-C levels in earlier studies lacking apoB data. For
example, the Suita study reveals that the prevalence of
CAD is markedly higher among individuals with hyper-
TG (>150 mg/dL) and -non-HDL-C (>190 mg/dL) [37].
According to our “alternative LDL window,” it is highly
likely that these subjects had high sdLDL-C levels.
Therefore, the “LDL window” may be useful for identify-
ing groups with high sdLDL-C levels in previous
literatures.
Fig. 3 The sdLDL-C levels stratified by the “LDL window” and the “alternative LDL window” of healthy subjects, patients with diabetes, and patients
with CAD. Top panel: small dense (sd) LDL-C levels stratified by triglycerides (TG) and apolipoprotein B (apoB) in healthy subjects (n = 1665), patients
with diabetes (n = 201), and patients with CAD (n = 528). The “LDL window” comprises the groups as follows: normal (apoB <110 mg/dL
and TG <150 mg/dL), hyper-TG (apoB <110 mg/dL and TG ≥150 mg/dL), hyper-apoB (apoB ≥110 mg/dL and TG <150 mg/dL), and hyper-TG/-apoB
(apoB ≥110 mg/dL and TG ≥150 mg/dL). Bottom panel: sdLDL-C levels stratified by TG and non-HDL-C in healthy subjects (n = 1665), patients with dia-
betes (n = 201), and patients with CAD (n = 528). The “alternative LDL window” comprises the groups as follows: normal (non-HDL-C <170 mg/
dL and TG <150 mg/dL), hyper-TG (non-HDL-C <170 mg/dL and TG ≥150 mg/dL), hyper-non-HDL (non-HDL-C ≥170 mg/dL and TG <150 mg/
dL), and hyper-TG/-non-HDL (non-HDL-C ≥170 mg/dL and TG ≥150 mg/dL).
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Conclusions
The “LDL window” identifies individuals with high
sdLDL-C levels. Therefore, we recommend that more
attention should be paid when TG and apoB (or non-
HDL-C) levels are high, particularly for patients with
diabetes and those with CAD, because their sdLDL-C
levels are likely to be substantially elevated.
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